Healthcare Industry News: Altair Therapeutics
News Release - January 8, 2009
Thomas, McNerney & Partners Promotes Three Members of Its Investment TeamKathy Tune Promoted to Principal. Christine Siu and Jason Brown, Ph.D. Promoted to Vice President
MINNEAPOLIS, SAN FRANCISCO and STAMFORD, Conn., Jan. 8 -- (Healthcare Sales & Marketing Network) -- Thomas, McNerney & Partners, a health care venture capital firm that invests in life science and medical technology companies, today announced the promotion of three members of its investment team. Kathy Tune has been promoted to Principal. Christine Siu and Jason Brown have been promoted to Vice President.
"We are pleased to announce the promotion of these three valuable members of our investment staff," said James Thomas, Partner. "Each of these individuals has made important contributions to the firm and these promotions recognize both their development as professionals and the growth and maturity of the firm and its investment team."
Kathy Tune joined the firm's Minneapolis office in 2003 and focuses her investment practice on the medical device sector. Kathy was previously with Piper Jaffray and Solvay. Kathy is a board member of Softscope Medical Technologies, Inc. Her educational background includes an M.S. degree in Microbiology from the University of Minnesota and an M.B.A. from the University of Minnesota's Carlson School of Management, where she was a Robert and Gail Buuck Scholar.
Christine Siu joined the firm's Connecticut office in 2005 and focuses her investment activities on venture opportunities in the public and late-stage private markets. Prior to Thomas, McNerney, Christine was at Warburg Pincus and Bear Stearns. Christine is a graduate of the University of Michigan with a B.S. with distinction in Cellular Molecular Biology and Economics and holds an M.B.A. from Harvard Business School.
Jason Brown joined Thomas, McNerney's San Francisco office in 2007 and focuses his investment practice in the biopharmaceutical sector. Jason previously spent four years at Forward Ventures and conducted research in antimicrobial drug discovery and bacterial genomics as a postdoctoral fellow in Infectious Diseases at Johnson & Johnson Pharmaceutical Research and Development. He is currently a board member of Altair Therapeutics, Inc. Jason earned a Ph.D. in Biology at the University of California, San Diego, where he was a National Science Foundation Fellow, and a B.S. in Molecular Biology and Biochemistry from Purdue University.
About Thomas, McNerney & Partners
Thomas, McNerney & Partners is a health care venture capital firm with approximately $600 million under management, focused on investing in life science and medical technology companies at all stages of development. In addition to helping entrepreneurs launch companies with seed and early-stage funding, the firm provides growth capital to emerging companies to advance clinical development or for product commercialization. Thomas, McNerney & Partners also is involved in spinning out products and divisions from major medical device and pharmaceutical companies, consolidating companies through roll-up strategies and participating in structured financings for public companies, as well as recapitalizations. The firm is targeting investments in the pharmaceutical, medical device, biotechnology and diagnostic sectors and in other areas utilizing medical technology innovation. The firm has offices in Stamford, Minneapolis and San Francisco.
For further information, please visit www.tm-partners.com.
Source: Thomas, McNerney & Partners
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.